Medicines360 acquires global rights to innovative pregnancy‑risk tools

The licensing of scientific discoveries from the University of Cambridge and the University of Edinburgh aims to accelerate translation and expand access to life‑saving diagnostics for women worldwide.

Medicines360, a women’s health innovation organisation, today announced it has acquired global licensing rights to new technologies designed to accurately predict the risk of conditions responsible for 50% of stillbirths, including novel blood biomarkers from the University of Cambridge and non-invasive retinal imaging from the University of Edinburgh.

“We are thrilled to be able to bring these technologies from the discovery stage through development. Our goal is to create lifesaving, innovative products and make them broadly available to all women from day one,”

said Dr. Andrea Olariu, CEO of Medicines360.

“Integrating these innovative risk assessment tools into routine prenatal care could dramatically reduce stillbirth rates globally.”

The newly licensed technologies were discovered and funded through Wellcome Leap’s In Utero program, a $50 million initiative to create scalable methods to measure, model, and predict gestational development. Medicines360 is collaborating with Wellcome Leap to translate scientific discoveries from their In Utero program into products that deliver precision insights across gestation, so that every pregnancy has the best chance of a healthy outcome. These include:

• The University of Cambridge’s new blood-based biomarker discoveries, which could identify the risk of common conditions associated with stillbirth, such as fetal growth restriction, gestational diabetes mellitus, and preeclampsia.
• The University of Edinburgh’s non-invasive retinal eye imaging technology, which aims to detect cardiovascular and metabolic changes during pregnancy.

Dr. Gordon Smith, Chair of the Obstetrics and Gynecology Department at the University of Cambridge and lead Principal Investigator of the In Utero discovery program said,

“The current approach to assessing stillbirth risk has not changed in 50 years. Our technologies, discovered using exceptionally robust clinical data, can provide clinicians with comprehensive risk stratification at every stage of pregnancy. Ultimately, we believe this approach will save the lives of mothers and babies.”

Dr Ione Meyer continued,

“By pairing Cambridge research excellence with a partner focused on women’s health, we’re accelerating solutions that can help clinicians identify risk sooner, personalise care, and improve outcomes for mothers and babies worldwide.”

Globally, there are more than two million stillborn babies every year. In the U.S., more than one in 150 births end in stillbirth – a burden disproportionately affecting families in low-income areas.

Dr. Rebecca Reynolds, Professor of Metabolic Medicine, the University of Edinburgh, who is being supported by Edinburgh Innovations, the University’s commercialization service said,

“Drawing on the world-class imaging facilities and data-science expertise at the University of Edinburgh, retinal imaging may provide personalized insights throughout pregnancy to assist clinicians with risk assessment for stillbirth, this is key to early detection, diagnosis, and an individualized approach to intervention.”

The licensing agreements advance the work of Medicines360’s M360 ASPIRE™ (Advancing Stillbirth Prevention through Innovative Risk Evaluation) Program. The M360 ASPIRE Program is redefining pregnancy care by developing novel biomarker technologies that enable risk prediction for conditions associated with stillbirth, to guide timely, life-saving interventions.

The technologies described are under development and have not been approved or cleared by the U.S. Food and Drug Administration or other regulatory authorities.

Image credits: Unsplash